MetaCap

Pacific Biosciences of California Inc. (PACB)

NASDAQ: PACBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

1.63-0.13 (-7.39%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PACB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$508.95M
EPS (TTM)
-$0.42
52-week range
1.07 – 3.44
Day range
1.61 – 1.73
Volume / Avg
13.68M / 13.23M
Beta
—

52-week range

$1.07$3.44

PACB stock today

Shares of Pacific Biosciences of California (PACB) finished lower on Nov 20 at $1.63, a drop of 7.39% or $0.13 per share, versus the S&P 500's 3.70% decline. At this level, PACB sits in the middle of its 52-week range of $1.07 to $3.44: 52.6% below the high, set on Oct 6, 2026 and 52.3% above the low. PACB is down 12.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.6%.

Pacific Biosciences of California has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pacific Biosciences of California

Company profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Mark Van Oene Ph.D.
Headquarters
Menlo Park, CA
Employees
485
IPO year
2010
Website
pacb.com

Financial highlights

Full financials

In fiscal 2025, Pacific Biosciences of California generated $160.0 million in revenue, up 3.9% from fiscal 2024. Pacific Biosciences of California reported a net loss of $546.4 million, compared with a loss of $309.9 million a year earlier. Gross margin was 28.6% (up from 24.2%) and operating margin -346.2%.

Pacific Biosciences of California annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$160.00M$154.01M$200.52M$128.30M$130.51M
Growth+3.89%-23.19%+56.29%-1.69%+65.43%
Net income$-546.38M$-309.85M$-306.74M$-314.25M$-181.22M
EPS (diluted)$-1.82$-1.59$-1.21$-1.40$-0.89

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$2.74+68.10%

  • Strong buy 0
  • Buy 4
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $2.00High $3.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.12 vs $-0.13
Surprise
+7.69%

PACB news

All PACB news

Pacific Biosciences of California peers

Industrials sector
PACB peer companies
CompanyPrice% ChgMarket capCompare
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs PACB
LABStandard BioTools Inc.0.631+2.82%$249.11Mvs PACB
CTKBCytek Biosciences Inc.6.12-3.16%$800.40Mvs PACB
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs PACB
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs PACB
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs PACB
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs PACB
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs PACB

Indexes, lists and sector

Pacific Biosciences of California stock FAQ

What is Pacific Biosciences of California's stock price today?

PACB last traded at $1.63 as of Nov 20, 4:00 PM EST, down 7.39% on the day. Prices are delayed at least 15 minutes.

Who is Pacific Biosciences of California's CEO?

Mr. Mark Van Oene Ph.D. is the chief executive officer of Pacific Biosciences of California Inc., which has about 485 employees.

What is the PACB 52-week high?

The 52-week high for PACB is $3.44 and the 52-week low is $1.07. The stock is currently 52.6% below its high.

Compare PACB